News in brief: Azithromycin ineffective in hospitalised COVID-19 patients; ICS-LABA long term safety data; OSA common in AF patients

Macrolide ineffective in hospitalised COVID-19 patients  Azithromycin does not improve survival or other important clinical outcomes in patients admitted to hospital with COVID-19. Data from almost 8,000 patients in the UK’s RECOVERY trial found deaths occurred at the same rate in patients treated with azithromycin and those receiving usual care (22% v 22%). Length of ...

Already a member?

Login to keep reading.

© 2021 the limbic